Panitumumab plus mFOLFOX6 therapy for colorectal cancer patients of RAS wild with potential resectable metastases in relation to early tumor shrinkage

Panitumumab plus mFOLFOX6 therapy for colorectal cancer patients of RAS wild with potential resectable metastases in relation to early tumor shrinkage - Panitumumab plus mFOLFOX6 therapy for RAS wild

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000012832

Enrollment

Registered

2014-01-15

Start date

2014-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

colorectal cancer with potential resectable metastases

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)histologically confirmed advanced mCRC ecept cancer of appendix and anal canal (2)Operable (3)RAS wild tye (4)Writen informed consent (5)Age: 20-80 years (6)Performance status (PS) 0-1 (7)Alife expectancy greater than 12 weeks (8)Metastases classified in Group 1 of ESMO Consensus Guidline (9)Adequate organ function

Exclusion criteria

Exclusion criteria: (1)Pleural effision or ascites or pericardial effusion to be discharged (2)Multiple malignacies to be treated (3)bleeding tendency(PT-INR ;1.5) (4)Ileus,uncontrollable peptic ulcer disease (5)Serious complications (DM, infection, diarrhea) (6)Serious heart disease (7)Previous history of severe drug-induced allergy (8)Severe neuropathy (9)With interstitial lung disease or pulmonary fibrosis (10)Pregnant (11)Disqualified by attending doctor

Design outcomes

Primary

Measure	Time frame
Early tumor shrinkage(at the point of 8 weeks)	—

Countries

Japan

Contacts

Public ContactGoro Nakayama

Nagoya University Graduate School of Medicine Gastroenterological Surgery

goro@med.nagoya-u.ac.jp052-744-2253

Outcome results